296 posters, 7 videos, 13 audios, 14 topics, 10 sessions, 1,019 authors, 260 institutions

RCOphth Annual Congress 2026

18 - 21 May, 2026 | Manchester Central, Manchester

Posters by Title

Showing 296 results.

Thumbnail for RCOphthGPT: a custom-trained AI companion for the new RCOphth 2024 curriculum and exams, supporting trainees and trainers with progression from Levels 1 to 4

P230

RCOphthGPT: a custom-trained AI companion for the new RCOphth 2024 curriculum and exams, supporting trainees and trainers with progression from Levels 1 to 4

Mohaimen Al-Zubaidy, Haidar Jafar, William Purcell, Zaid Alsafi, Yashin Ramkissoon

Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK, University of Sheffield, Sheffield, UK, University of Liverpool, Liverpool, UK, Moorfields Eye Hospital NHS...

Poster Presenter: Mohaimen Al-Zubaidy

Thumbnail for Re- audit: Quality of documentation of ophthalmic findings in infants and young children with suspected non- accidental injury (NAI): A Medicolegal prospective

P266

Re- audit: Quality of documentation of ophthalmic findings in infants and young children with suspected non- accidental injury (NAI): A Medicolegal prospective

Rehana Sadia, William Newman

Poster Presenter: Rehana Sadia

RCOphth Annual Congress 2026

Posters by Title

RCOphthGPT: a custom-trained AI companion for the new RCOphth 2024 curriculum and exams, supporting trainees and trainers with progression from Levels 1 to 4

Re- audit: Quality of documentation of ophthalmic findings in infants and young children with suspected non- accidental injury (NAI): A Medicolegal prospective

Real world comparative results of three commonly used MIGS, Hydrus, Istent and OMNI.

Real world effectiveness of faricimab in treatment experienced eyes with macular oedema secondary to retinal vein occlusion.

Real World Patient Experience with Autonomous Clinical Consultations: A 3-Year Analysis of over 145,000 Interactions Across NHS Cataract Pathways

Real-world 12 and 18-month outcomes of faricimab in patients previously treated for neovascular age-related macular degeneration.

Real-World Outcomes in Neovascular Age-Related Macular Degeneration Following Transition to Eylea HD

Real-World Outcomes of Half-Dose Photodynamic Therapy for Central Serous Chorioretinopathy: A 7-Year Audit from a UK Tertiary Eye Unit

Real-World Outcomes of Intravitreal Dexamethasone Implant (Ozurdex�) as First-Line Therapy for Diabetic Macular Oedema